Erasca, Inc. is a clinical-stage biopharmaceutical company dedicated to finding treatments for RAS/MAPK pathway-driven cancers. Their notable candidates include ERAS-007, an ERK1/2 inhibitor for patients with various types of cancer, and ERAS-601, an SHP2 inhibitor for people with advanced or metastatic solid tumors. ERAS-801, an EGFR inhibitor for glioblastoma multiforme patients, is also being developed by the company, which was founded in 2018 and is headquartered in San Diego, California.